• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen Announces R&D Program Update

by mfantozzi | Jul 2, 2021 | 2021, Press Releases, Scientific

Fibromun shows activity in pretreated glioma and sarcoma patients; OncoFAP targets tumor lesions in cancer patients; a new product partnered with AbbVie entered clinical studies  Read more

Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress

by last | May 12, 2021 | 2021, Press Releases, Scientific

  COMUNICATO STAMPA 05-12-2021   PRESS RELEASE – 2021-05-12

Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNAS

by last | May 4, 2021 | 2021, Press Releases, Scientific

Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs. OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer. Philogen announces participation to the 10th World Congress of Melanoma...

Philogen announced Option and License Agreement with Pfizer Inc.

by last | Dec 22, 2014 | 2014, Press Releases, Scientific

Philogen announced Option and License Agreement with Pfizer Inc. to develop and commercialize multiple antibody drug conjugates and targeted nano particles. (see full press release). Siena (Italy), December 22nd, 2014.

Dario Neri – presented ‘Immunocytokines for the therapy of cancer and of chronic inflammation’ at Antibody Engineering and Therapeutics conference

by last | Dec 7, 2014 | 2014, Press Releases, Scientific

Dario Neri – presented ‘Immunocytokines for the therapy of cancer and of chronic inflammation’ at Antibody Engineering and Therapeutics conference. Huntingdon Beach, California (USA), December 7th-11th, 2014.
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch